Adjuvant Capital — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsIndustrifondenOrbiMedPureos BioventuresSanofi VenturesSunstone CapitalEQT Life Sciences+2 more
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)
Co-investorsBrace PharmaCanaan PartnersLumira VenturesMPM BioImpactOUP (Osage University Partners)Sofinnova Ventures+3 more
Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses.
BiotechDeep TechHealthtechFarmingdale, US
John Robert Coleman(Executive Officer, Director)Steffen Mueller(Director)Charlie Petty(Director)Steven Winick(Director)Jill Howe(Director)Paul Grint(Director)
Co-investorsIn-Q-TelTopspin Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.